Moderna announces IND submitted to US FDA for phase 2 study of mRNA-1273 against novel coronavirus

This article was originally published here

Moderna has received initial feedback from the FDA on the design of the planned Phase 2 study, which is expected to begin in the second quarter of 2020.

The post Moderna announces IND submitted to US FDA for phase 2 study of mRNA-1273 against novel coronavirus appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply